Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ERN1 | O75460 | 3/20 | 0.35 |
| ▸ | BRD2 | P25440 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27599899 | 0.74 | BRD4 (0.41) | BRD4KMT2AERN1BRD2MEN1 | |
| SCHEMBL4554973 | 0.72 | — | — | |
| SCHEMBL19287104 | 0.71 | MAPT (0.51) | BRD4KMT2ABRD2MEN1ALDH1A1 | |
| SCHEMBL20016686 | 0.70 | — | — | |
| SCHEMBL18884406 | 0.70 | — | — | |
| SCHEMBL3599701 | 0.70 | BRD4 (0.46) | BRD4KMT2ABRD2MEN1ALDH1A1 | |
| SCHEMBL18904014 | 0.70 | KMT2A (0.35) | BRD4KMT2ABRD2ALDH1A1L3MBTL1 | |
| SCHEMBL1747763 | 0.70 | KMT2A (0.35) | BRD4KMT2ABRD2ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL1375757 | 0.68 | BRD4 (0.45) | BRD4KMT2ABRD2MEN1ALDH1A1 | |
| SCHEMBL8260822 | 0.68 | RIPK1 (0.44) | BRD4KMT2ABRD2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817036-B1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMA (US) | 2012-07-04 | — | — | EP | claimed |
| US-20110257153-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICAL NV | 2011-10-20 | — | — | US | claimed |
| EP-2217237-A1 | ARYL-SUBSTITUTED BRIDGED OR FUSED DIAMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Janssen Pharmaceutica N.V. (BE) | 2010-08-18 | — | — | EP | claimed |
| WO-2009058347-A1 | ARYL-SUBSTITUTED BRIDGED OR FUSED DIAMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-07 | — | — | WO | claimed |
| US-20090111794-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | claimed |
| US-20070004765-A1 | New compounds | BIOVITRUM AB (SE) | 2007-01-04 | — | — | US | claimed |
| WO-2006122931-A1 | BETA-CARBOLINE DERIVATIVES AND THERI USE AS GHSR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2006-11-23 | — | — | WO | claimed |
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | BIOVITRUM AB (SE) | 2005-12-29 | — | — | US | claimed |
| WO-2005048916-A2 | TETRAHYDROSPIRO-BETA-CARBOLINE-1,3 '-PYRROLIDINE DERIVATIVES AND THEIR USE IN GHSR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2005-06-02 | — | — | WO | claimed |
| EP-2493886-B1 | HETEROARYL PIPERIDINE AND PIPERAZINE DERIVATES | BAYER CROPSCIENCE AG (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-8501781-B2 | Heteroarylpiperidine and -piperazine derivatives | BAYER CROPSCIENCE AG (DE) | 2013-08-06 | — | — | US | disclosed |
| US-8367719-B2 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-05 | — | — | US | disclosed |
| US-8344008-B2 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A ydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-01 | — | — | US | disclosed |
| EP-2493886-A1 | HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES | Bayer CropScience AG (DE) | 2012-09-05 | — | — | EP | disclosed |
| US-20070004765-A1 | New compounds | BIOVITRUM AB (SE) | 2007-01-04 | — | — | US | disclosed |
| WO-2006122931-A1 | BETA-CARBOLINE DERIVATIVES AND THERI USE AS GHSR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2006-11-23 | — | — | WO | disclosed |
| CN-1269813-C | Imidazolo-5-yl-2-anilino-pyrimidines as agents for inhibition of cell proliferation | ASTRAZENECA AB (SE) | 2006-08-16 | — | — | CN | disclosed |
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | BIOVITRUM AB (SE) | 2005-12-29 | — | — | US | disclosed |
| WO-2005048916-A2 | TETRAHYDROSPIRO-BETA-CARBOLINE-1,3 '-PYRROLIDINE DERIVATIVES AND THEIR USE IN GHSR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2005-06-02 | — | — | WO | disclosed |
| EP-1351958-B1 | IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2004-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | GHSR, GHRHR, PRLHR | BRD4 1031/4885KMT2A 2414/4885ERN1 4439/4885 |
| US-20090111794-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | BRD4 281/4885KMT2A 2154/4885ERN1 3604/4885 |
| US-20070004765-A1 | New compounds | GHSR, GIPR, PRLHR | BRD4 1384/4885KMT2A 3641/4885ERN1 4504/4885 |
| US-20110257153-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | BRD4 281/4885KMT2A 2154/4885ERN1 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.